Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Abdom Imaging 2004; 30 (1): 65-68. FI: 0,996<br />
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodríguez S, Arribas J, Palacios<br />
J, Baselga J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839)<br />
and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res.<br />
2004; (19): 6487-501. FI: 6,511<br />
Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun<br />
N, Losa I, Guillem V, García-Conde J, Tisaire JL, Baselga J. A multicentre, randomised phase II study of weekly or 3-<br />
weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004; (9): 1358-65. FI: 3,605<br />
Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S,<br />
Harstrick A, Baselga J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody<br />
EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol.<br />
2004; (1): 175-84. FI: 10,864<br />
Vila MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, Bellmunt J. Hepatitis A virus receptor blocks cell differentiation<br />
and is overexpressed in clear cell renal cell carcinoma. Kidney Int. 2004; 65(5): 1761-73. FI: 5,302<br />
Villanueva de la Torre T, Bech-Serra JJ, Ruíz-Paz S, Baselga J, Arribas J. Inactivating mutations block the tumor necrosis<br />
factor-alpha-converting enzyme in the early secretory pathway. Biochem Biophys Res Commun. 2004; 314(4):<br />
1028-35. FI: 2,836<br />
Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol. 2004; 31 (5 Suppl 10):<br />
6-13. FI: 4,733<br />
Projectes de recerca actius<br />
IP: José Baselga Torres.<br />
«Optimización del tratamiento antitumoral con inhibidores del Receptor del Factor de Crecimiento Epidérmico (EGFR)<br />
y sus vías de señalización mediante el uso».<br />
Entitat finançadora: Ministerio de Ciencia y Tecnología.<br />
Nº Expedient: 2003-03818<br />
Import: 132 100 €<br />
Durada: des de 2003 fins a 2006.<br />
IP: José Baselga Torres.<br />
«The PI3-K/Akt/mTOR pathway: A novel target for breast cancer therapy».<br />
Entitat finançadora: The Breast Cancer Research Foundation.<br />
Nº Expedient: 2003/TBCRF/’01<br />
Import: 750 000 €<br />
Durada: des de 2003 fins a 2006.<br />
39
Change language